Oncotype DX
Genomic test that analyzes tumor genes to predict chemotherapy benefit and recurrence risk.
Full Definition
Oncotype DX is a multi-gene expression assay that analyzes 21 genes in early-stage, hormone receptor-positive breast cancer tissue to predict the likelihood of chemotherapy benefit and risk of distant recurrence. The test provides a Recurrence Score between 0 and 100, helping oncologists and patients make informed decisions about adjuvant chemotherapy. Results are categorized as low, intermediate, or high risk, with treatment recommendations varying accordingly. This genomic test has become an important tool in personalizing breast cancer treatment and avoiding unnecessary chemotherapy in appropriate patients.
Usage
Usage note: Capitalize both words; do not hyphenate.
In Context
- "The Oncotype DX score of 18 suggested intermediate risk for recurrence." — Pathology report
- "Oncotype DX testing is recommended for hormone receptor-positive, node-negative breast cancer." — Treatment guideline